

1 **The relative strength and timing of innate immune and CD8 T-cell responses**  
2 **underlie the heterogeneous outcomes of SARS-CoV-2 infection**

3

4 Budhaditya Chatterjee<sup>1,†</sup>, Harshbir Singh Sandhu<sup>2,†</sup>, Narendra M. Dixit<sup>1,2,\*</sup>

5

6 <sup>1</sup>Centre for Biosystems Science and Engineering, Indian Institute of Science, Bangalore, India 560012

7 <sup>2</sup>Department of Chemical Engineering, Indian Institute of Science, Bangalore, India 560012

8

9 <sup>†</sup>These authors contributed equally

10

11 \*Correspondence: [narendra@iisc.ac.in](mailto:narendra@iisc.ac.in)

12

13 **Short title: Modeling the heterogeneous outcomes of COVID-19**

14

15 **Manuscript details:**

16 Title: 134 characters; Abstract: 150 words; Figures: 4; References: 94

17 Supplementary materials: Text notes: A-E; Tables: 12; Figures: 12

18 **Abstract**

19 SARS-CoV-2 infection results in highly heterogeneous outcomes, from cure without symptoms to acute  
20 respiratory distress and death. While immunological correlates of disease severity have been identified,  
21 how they act together to determine the outcomes is unknown. Here, using a new mathematical model of  
22 within-host SARS-CoV-2 infection, we analyze diverse clinical datasets and predict that a subtle interplay  
23 between innate and CD8 T-cell responses underlies disease heterogeneity. Our model considers essential  
24 features of these immune arms and immunopathology from cytokines and effector cells. Model  
25 predictions provided excellent fits to patient data and, by varying the strength and timing of the immune  
26 arms, quantitatively recapitulated viral load changes in mild, moderate, and severe disease, and death.  
27 Additionally, they explained several confounding observations, including viral recrudescence after  
28 symptom loss, prolonged viral positivity before cure, and mortality despite declining viral loads.  
29 Together, a robust conceptual understanding of COVID-19 outcomes emerges, bearing implications for  
30 interventions.

31

32 **Teaser**

33 Modeling explains how a subtle interplay between innate immune and CD8 T-cell responses determines  
34 the severity of COVID-19.

## 35 Introduction

36 Coronavirus disease 2019 (COVID-19), a respiratory infection caused by the severe acute respiratory  
37 syndrome coronavirus 2 (SARS-CoV-2), evokes remarkably heterogeneous clinical outcomes (1, 2).  
38 While some individuals are cured without any symptoms, others suffer mild to moderate symptoms, and  
39 yet others experience severe disease requiring hospitalization and intensive care, with a sizeable fraction  
40 of the latter suffering death (1–3). Several demographic correlates of disease severity, such as gender, co-  
41 morbidities, and age, have been identified (4). Further, immunological correlates of severe disease  
42 outcomes, such as a subdued early innate immune response (5), and a late surge of proinflammatory  
43 cytokines (6, 7) have also been reported. Yet, what determines this diversity of outcomes has remained an  
44 outstanding question, challenging our understanding of infectious disease biology and, more immediately,  
45 precluding optimal strategies for combating the raging COVID-19 pandemic.

46 While viral factors, including emerging mutations (8), may have a role in determining the outcomes, the  
47 heterogeneous outcomes were reported in early studies (2, 3), before the majority of the clades of SARS-  
48 CoV-2 emerged (9), suggesting that the heterogeneity potentially originates from the variability in the  
49 host immune responses to the infection (6). Rapidly accumulating evidence reinforces the role of the  
50 immune response, particularly of the innate and the CD8 T-cell responses, in determining disease  
51 outcomes: Soon after infection, an innate immune response is first mounted, involving the production of  
52 cytokines, particularly type I and type III interferons, by virus-infected and immune cells (10). Interferons  
53 work across viruses and, through autocrine and paracrine signaling mechanisms, can reduce viral  
54 production from infected cells and render proximal target cells temporarily resistant to infection,  
55 controlling disease progression (10, 11). With SARS-CoV-2, patients with mild disease had higher levels  
56 of interferons in their upper respiratory airways than those with more severe disease, suggesting that  
57 robust innate immune responses contribute to reduced severity of infection (5).

58 A few days into the infection, the adaptive immune response involving virus-specific effector CD8 T-  
59 cells is triggered. CD8 T-cells are thought to play a critical role in the clearance of SARS-CoV-2 (7): The  
60 earlier the first detectable CD8 T-cell response, the shorter is the duration of the infection (12). CD8 T-  
61 cell numbers were higher in the bronchoalveolar lavage fluids of individuals with mild/moderate  
62 symptoms than in those with severe infection (13). Clonal expansion of CD8 T-cells was compromised in  
63 patients with severe symptoms (13, 14). Infected individuals often suffer lymphopenia (15, 16), with the  
64 extent of lymphopenia correlated with disease severity (15, 17). Finally, the severity of the symptoms was  
65 proportional to the level of exhaustion of CD8 T-cells (15, 17). Accordingly, a combination of the innate  
66 and CD8 T-cell responses appears to drive viral clearance.

67 Once the disease is resolved, typically in 2-3 weeks, the cytokines and activated CD8 T-cell populations  
68 decline and eventually fade away, leaving behind memory CD8 T-cells (7). If the disease is not resolved  
69 in a timely manner, uncontrolled cytokine secretion may result, triggering immunopathology and severe  
70 disease (6). Indeed, an elevated interferon response was detected in the lower respiratory tracts of  
71 severely infected and deceased patients (5, 18, 19), with the lung suffering the most damage (20). Innate  
72 immune cell-types, such as neutrophils, macrophages and natural killer cells, which are thought not to  
73 contribute significantly to clearance, may nonetheless worsen the damage (6, 21). Prolonged disease,  
74 where viral load could be detected in patients over extended durations—up to 66 days on average in some  
75 cohorts—has been reported (22–24). Proliferation and differentiation of CD8 T-cells were compromised in

76 prolonged SARS-CoV-2 positive patients (22). The innate immune and CD8 T-cell responses thus appear  
77 to be involved in these undesirable outcomes of the infection as well.

78 Antibodies, the other component of the adaptive immune response, arise much later, a couple of weeks  
79 into the infection (7, 25). While important in vaccine-mediated protection (26, 27), their role in clearing  
80 infection in the unvaccinated is thought to be less significant than that of CD8 T-cells (7). Antibody titers  
81 are higher in severely infected than in mildly infected individuals (7). Whereas a subset of antiviral  
82 antibodies possibly contribute to the clearance of infection (28), autoantibodies, typically generated in  
83 COVID-19 patients, against cytokines and cell surface and structural proteins of the host, may adversely  
84 affect clinical outcomes (29).

85 Based on these observations, we hypothesized that the strength and the timing of the innate and the CD8  
86 T-cell responses were the predominant factors responsible for the heterogeneous outcomes of SARS-  
87 CoV-2 infection. To test this hypothesis, we developed a mathematical model of within-host SARS-CoV-  
88 2 dynamics that incorporated the key features of the innate and the CD8 T-cell responses. We validated  
89 the model against patient data and employed it to elucidate the interplay of the two immune arms in the  
90 outcomes realized.

## 91 **Results**

### 92 **Mathematical model of within-host SARS-CoV-2 dynamics**

93 We considered an individual infected by SARS-CoV-2. We modeled disease progression in the individual  
94 by following the time-evolution of the population of infected cells ( $I$ ), the strength of the effector CD8 T-  
95 cells ( $E$ ), the cytokine-mediated innate immune response ( $X$ ), and tissue damage ( $D$ ) (Figure 1). We  
96 considered the essential interactions between these entities (30) and constructed the following equations  
97 to describe their time-evolution:

$$\begin{aligned} 98 \quad \frac{dI}{dt} &= k_1(1 - \varepsilon_I X)I \left(1 - \frac{I}{I_{max}}\right) - k_2 I E \\ 99 \quad \frac{dE}{dt} &= k_3 \left(\frac{IE}{k_p + I}\right) - k_4 \left(\frac{IE}{k_e + I}\right) \\ 100 \quad \frac{dX}{dt} &= k_5 I - k_6 X \\ 101 \quad \frac{dD}{dt} &= \alpha I E + \beta X - \gamma D \end{aligned}$$

102 Here, the infected cells follow logistic growth (30), with a per capita growth rate  $k_1$  and carrying capacity  
103  $I_{max}$ . This growth represents the infection of target cells by virions produced by infected cells (30).  $I_{max}$   
104 is the maximum number of cells that can get infected, due to target cell or other limitations. The growth  
105 rate  $k_1$  is assumed to be reduced by the innate immune response,  $X$ , with the efficacy  $\varepsilon_I X$ , due to  
106 interferon-mediated protection of target cells and/or lowering of viral production from infected cells (10).  
107 Effector cell-mediated killing of infected cells is captured by a mass action term with the second-order  
108 rate constant  $k_2$ . The proliferation and exhaustion of CD8 T-cells are both triggered by infected cells at  
109 maximal per capita rates  $k_3$  and  $k_4$ , respectively.  $k_p$  and  $k_e$  are the levels of infected cells at which the  
110 proliferation and exhaustion rates are half-maximal, respectively. Following previous studies, we let  $k_3 <$




128 contracting the disease is rarely known. Because the prodromal period may vary substantially across  
129 individuals (35), measurements from symptom onset may miss the initial phases of the immune response,  
130 which can be an important determinant of disease outcome. In asymptomatic individuals, this early  
131 response clears the infection (36). We therefore sought datasets that included accurate estimates of the  
132 time of contracting the disease. Fortunately, we found such data in a study of one of the first SARS-CoV-  
133 2 transmission chains in Germany in early 2020 (37, 38). The study traced the dates of first exposure to  
134 the virus for each patient in the transmission chain (38) (supplementary text section A; supplementary  
135 table S1). Further, daily viral load data, measured in nasopharyngeal swab and sputum samples, for all  
136 patients starting from the onset of symptoms or earlier were reported (37). Data from the nasopharyngeal  
137 swabs are thought not to be the best correlates of disease outcome and severity (39). The sensitivity of  
138 SARS-CoV-2 detection in sputum is substantially higher than in nasopharyngeal swabs (40). We  
139 therefore employed data from the sputum samples in this study. We considered data from day zero to day  
140 15 into the infection (supplementary text section A; supplementary tables S1-S3). Beyond two weeks, the  
141 humoral response is mounted in most patients (7, 25), the role of which, as mentioned above, is poorly  
142 understood (7).

143 We fit our model to the above viral load data, representing the dynamics of the infection and immune  
144 responses in the respiratory tract. All patients in this dataset had mild symptoms, which waned by day 7  
145 after the first virological test. The patients were of working age and otherwise healthy. In such patients,  
146 markers of T-cell exhaustion are not significantly higher than healthy individuals and are markedly lower  
147 than severely infected patients (15). Therefore, to facilitate more robust parameter estimation, we ignored  
148 CD8 T-cell exhaustion in the present fits (by fixing  $k_4 = 0$ ). Furthermore, we assumed that the viral  
149 population,  $V$ , is in a pseudo-steady state with the infected cell population, so that  $V \propto I$ . Since, the  
150 dynamics of tissue damage ( $D$ ) is dependent on but does not affect the dynamics of infected cells ( $I$ ), CD8  
151 T-cells ( $E$ ) and the cytokine mediated innate response ( $X$ ), in our model, we ignored  $D$  for the present  
152 fitting. This is further justified because the patients considered for fitting are mildly/moderately infected,  
153 and are expected to suffer minimal tissue damage. Because the patients were all similar, we assumed that  
154  $I_{max}$  would be similar in them and proportional to  $V_{max}$ , the highest viral load reported across the  
155 patients. We thus fit  $\log_{10}(I/I_{max})$  calculated with our model to the normalized data of  $\log_{10}(V/V_{max})$ .  
156 Our fits were not sensitive to  $I_{max}$  (supplementary tables S4, S5). We allowed a delay following exposure  
157 to account for the incubation period before viral replication can begin. We used a nonlinear mixed-effects  
158 modelling approach for parameter estimation (41). Our model provided good fits to the data (figure 2,  
159 first column of subplots) and yielded estimates of the parameters at the population-level (supplementary  
160 table S6) and for the individual patients (supplementary table S7).

161 To ascertain the robustness of our model and fits, we tested several variants of our model. We fit variants  
162 without the adaptive response, without the innate response, with a logistic growth formulation of the  
163 innate immune response, with the innate response amplifying the adaptive response, or combinations  
164 thereof to the same data (supplementary text section B, supplementary table S8). The fits were all poorer  
165 than the present model (figure 1, supplementary table S8). We thus employed our present model for  
166 further analysis.

---



167

168 **Figure 2: Fits of the mathematical model to patient data.** X-axis represents time from viral exposure in  
169 all subplots. The quantity plotted on the Y-axis for all subplots in a given column is mentioned at the top of  
170 the column. The first column shows data from patients in open circles (37). These represent normalized  
171 viral loads from sputum samples. Best-fit model predictions are shown as black curves. Patient IDs as



172 provided in Böhmer et al. (38) are in the top-left corner of each subplot. The magenta curves in the  
173 second column, the blue area plots in the third column and the green area plots in the fourth column  
174 represent the corresponding dynamics of infected cells, cytokine mediated innate immune response and  
175 effector CD8 T-cell mediated adaptive immune response, respectively. Parameter values used are listed  
176 in supplementary table S7.

---

177

## 178 **Model elucidates distinct patterns of viral clearance and associated immune responses**

179 The best-fits above yielded important insights into the underlying dynamics of disease progression and  
180 clearance. First, the time between viral exposure and noticeable escalation of the viral load, i.e., the post-  
181 exposure delay in viral replication, varied from 0.8 d to 6.6 d in the patients analyzed, with a mean of  
182  $2.7 \pm 0.8$  days, reflecting the variability in the time of the establishment of systemic infection following  
183 exposure, and consistent with the variable prodromal period observed (35). The initial, possibly stochastic  
184 (42), events during the establishment of infection might be associated with the variability in the delay in  
185 viral replication. Second, our model offered an explanation of the two distinct patterns of clearance  
186 observed in the patients. Patients 1, 2, 3, 4, and 14 had a single peak in viral load (or infected cell  
187 numbers) followed by a decline of viral load leading to clearance (figure 2, second column of subplots).  
188 Patients 7, 8 and 10, in contrast, had a second peak following the first. Our model predicted these distinct  
189 patterns as arising from the temporal variation in the dynamics of the innate and CD8 T-cell responses.

190 The interactions between the innate response,  $X$ , and infected cells,  $I$ , in our model have signatures of the  
191 classic predator-prey system (43) with  $I$  the prey and  $X$  the predator: In the absence of  $X$ ,  $I$  grows.  $I$  also  
192 triggers  $X$ , which in turn suppresses  $I$ .  $X$  declines in the absence of  $I$ . These interactions, as with the  
193 predator-prey system (43), predict oscillatory dynamics. Thus, following infection,  $I$  grows, causing a rise  
194 of  $X$  in its wake. When  $X$  rises sufficiently, it suppresses  $I$ . When  $I$  declines substantially, the production  
195 of  $X$  is diminished and  $X$  declines. This allows  $I$  to rise again and the cycle repeats. This cycle is broken  
196 in our model by CD8 T-cells,  $E$ . Viral clearance is not possible in our model without  $E$  (supplementary  
197 figure S1). When  $E$  rises, it can suppress  $I$  independently of  $X$ , breaking the cycle and allowing  $X$  to  
198 dominate  $I$ . Together,  $X$  and  $E$  can then clear the infection. In patients 7, 8, and 10, our best-fits predicted  
199 an early innate immune response and a delayed CD8 T-cell response. The second peak was thus predicted  
200 as a result of the above predator-prey oscillations that occurred before the CD8 T-cell response was  
201 mounted. In patients 3, 4, and 14, a relatively early CD8 T-cell response was predicted, which precluded  
202 the second peak. In patients 1 and 2, both the innate and CD8 T-cell responses were delayed, leaving little  
203 time for the oscillations to arise in the 15 d period of our observations. We note that interpretations of the  
204 multiple peaks in longitudinal viral load data have not been forthcoming (44). Our predictions offer a  
205 plausible interpretation.

206 Third, the transient but robust innate immune response predicted (figure 2, third column of subplots) is  
207 consistent with observations in mildly infected patients (45). Fourth, our prediction of the dynamics of the  
208 CD8 T-cell response, where a gradual build-up is followed by a stationary phase (figure 2, fourth column)  
209 is also consistent with observations. In mildly infected patients, SARS-CoV-2 specific T-cells were  
210 detected as early as 2-5 days post symptom onset (12). This effector population remained stable or  
211 increased for several months after clinical recovery (16, 46).

212 Our model thus fit the dynamics of infection in individuals showing mild symptoms and offered  
213 explanations of disease progression patterns that had remained confounding. We examined next whether



214 the model could also describe more severely infected patients. For this, we varied different parameters in  
215 our model and assessed the resulting dynamical features of the infection.

## 216 **Interplay between innate and CD8 T-cell responses underlies heterogeneous disease outcomes**


217 We reintroduced the CD8 T-cell exhaustion term, which we had ignored in the fits above because the  
218 patients were mildly infected, and selected associated parameter estimates from previous studies (30). We  
219 ensured that this did not affect our fits above (supplementary figure S2).

220 Next, to estimate the severity of the disease, we also examined the dynamics of the instantaneous tissue  
221 damage ( $D$ ). Typically,  $D$  rose as the infection progressed and declined as it got resolved (supplementary  
222 figure S3A, C). We reasoned that the severity of infection would be determined by the maximum tissue  
223 damage suffered and the duration for which such damage lasted. Significant damage that is short-lived or  
224 minimal damage that is long-lived may both be tolerable and lead to mild symptoms. We therefore  
225 calculated the area under the curve (AUC) of  $D$ , starting from when  $D$  ascended above its half-maximal  
226 level to the time when it descended below that level (supplementary figure S3A), as a measure of  
227 immunopathology ( $P$ ) and associated disease severity. (Note that the parameters  $\alpha$ ,  $\beta$ , and  $\gamma$ , which  
228 describe the dynamics of tissue damage, are unknown constants; our results were not sensitive to their  
229 values because changing them only minimally affected the relative extents of immunopathology across  
230 different disease severity categories (supplementary text section C; supplementary figure S5).)

231 With this framework, we varied the strengths of the CD8 T-cell and innate responses, by changing the  
232 values of the parameters  $k_3$  and  $k_5$ , respectively, and examined the predicted dynamical features (figure  
233 3A). Recall that  $k_3$  is the proliferation rate of CD8 T-cells and  $k_5$  is the rate of generation of the innate  
234 immune response. The other parameters were fixed (supplementary table S6) at their population  
235 estimates, for which the model elicited clearance of the infection by day 14 (figure 3A, center, subplot  
236 with an arrowhead). Increasing  $k_5$  resulted in a decrease in the peak of infected cells (figure 3A, the row  
237 of subplots with arrowhead, right to left). With decrease in  $k_5$ , the induction of the cytokine mediated  
238 antiviral innate response was substantially delayed and that corresponded to an increased number of  
239 infected cells (supplementary figure S4A, B). Clearance was achieved in all cases without substantial  
240 variation in the infection duration because of the CD8 T-cell response (figure 3A, the row of subplots  
241 with arrowhead, right to left). Decreasing  $k_3$  weakened the CD8 T-cell response and increased the  
242 duration of the infection (figure 3A, the column of subplots with arrowhead, bottom to top). We next  
243 explored the effects of varying both  $k_3$  and  $k_5$  simultaneously.

244 When  $k_3$  was high, *i.e.*, the response of CD8 T-cells was strong, irrespective of the innate immune  
245 response, the infection was cleared within ten days (figure 3A, subplots on bottom-left and bottom-right).  
246 Associated immunopathology was nominal. These predictions were akin to asymptomatic and mild  
247 infection scenarios. An early and robust effector T-cell response has been associated with milder  
248 infections (12, 16, 46). Here, in some cases with high  $k_5$ , a blip of the viral load was observed after an  
249 initial phase of clearance. When  $k_5$  was decreased, marking a weaker innate response, the peak viral load  
250 rose and immunopathology moderately increased. This was also observed when we decreased  $\epsilon_I$ , which  
251 lowered the efficacy with which the innate immune response inhibits the spread of the infection (figure  
252 3B). The latter trends associated with high  $k_3$  and low  $k_5$  have parallels to infected patients with robust  
253 CD8 T-cell responses but impaired innate responses, such as those harboring mutations in the genes

254 associated with the activation of the antiviral resistance in host cells (47). Clearance was achieved in such  
 255 cases due to the robust CD8 T-cell response.



256

257 **Figure 3: Variations in innate and CD8 T-cell responses capture disease heterogeneity.** (A) Effect of  
258 simultaneous variation of parameters determining the strengths of innate and CD8 T-cell responses. The  
259 black, annotated triangles at the top and right indicate the nature and the direction of the variation of the  
260 indicated parameters. For instance,  $k_5$  is decreased from left to right. Individual subplots show the  
261 dynamics of infected cells normalized by carrying capacity, cytokine mediated innate immune response  
262 and effector CD8 T-cell mediated adaptive immune response. The legends are provided at the top-right.  
263 The left Y-axis shows the normalized infected cell dynamics. The right Y-axis shows the other two  
264 species, i.e., cytokine-mediated innate immune response and effector CD8 T-cell-mediated adaptive  
265 immune response. The rectangular, colored patch at the top of each subplot represents the extent of  
266 immunopathology. The range of immunopathology is given by the color scale at the bottom of the figure  
267 (below 3C). At the left of the color scale, a separate legend denotes the texture used for depicting  
268 diverged immunopathology. The arrowhead on the scale indicates the immunopathology for the  
269 population parameters. The central subplot, which also contains an arrowhead, charts the simulation  
270 using the population parameters (supplementary table S6). (B, C) Similar calculations corresponding to  
271 variations in other parameters associated with the innate (B) and CD8 T-cell (C) responses. Plots with the  
272 population parameters are marked with the arrowhead. The colored patches should be interpreted using  
273 the color scale provided at the bottom.

274 When  $k_3$  was low and  $k_5$  was high (figure 3A, four subplots on top-left), the infection was prolonged.  
275 However, the immunopathology was lower than when both  $k_3$  and  $k_5$  were high. The efficient antiviral  
276 innate response controlled the initial peak of the infection. However, the slow proliferation of the effector  
277 cells delayed clearance. This scenario had parallels to the reported cases of prolonged RT-PCR positivity  
278 of viral loads (22–24). Restrained CD8 T-cell differentiation was associated with such cases (22).  
279 Delayed clearance was also realized when the parameter  $k_p$  was increased, which increased the antigen  
280 level required for significant effector T-cell proliferation (figure 3C). These predictions were consistent  
281 with observations of defects in T-cell proliferation delaying the clearance of infection (22).


282 When both  $k_3$  and  $k_5$  were low (figure 3A, four subplots on top-right), severe immunopathology along  
283 with prolonged infection with high viral load and high cytokine levels was predicted. When they were the  
284 lowest, clearance was not achieved in our simulations. Although, clearance of the infection is the  
285 predominant outcome associated with a wide range of parameter values (figure 3), our dynamical systems  
286 analysis revealed that in certain parameter regimes clearance may not result (supplementary text section  
287 D, supplementary figures S6, S7). Instead, escape from immune protection with a high level of infected  
288 cells and cytokines together with a high degree of CD8 T-cell exhaustion may occur. Such runaway  
289 trajectories were associated with high immunopathology in our model (figure 3A, top right corner,  
290 supplementary figure S3B, S3C, top right corner) and were predicted to be terminated by fatality. These  
291 trends in the model mirrored clinical features of severe COVID-19 (45), which include consistently very  
292 high viral loads, heightened proinflammatory cytokines and interferons (39, 45, 48), attenuated  
293 proliferation (13) and increased exhaustion of T-cells (13, 14, 17). The predictions also include cases  
294 where in the late phase of the infection, although the viral load in sputum shows a decline (49), and that in  
295 nasopharyngeal swab becomes undetectable (33, 39, 49), mortality results due to intolerable  
296 immunopathology.

297 Note that the initial pool of CD8 T-cells,  $E_0$ , was important in determining outcomes (supplementary text  
298 section D, supplementary figure S7), with a large pool leading to rapid clearance, in agreement with  
299 observations of such clearance facilitated by cross-reactive effector T cells (12, 50). The outcomes were

300 less sensitive to the viral inoculum size (supplementary text, section E, supplementary figure S8), i.e.,  $I_0$ ,  
301 consistent with studies on macaques where different inoculum sizes led to comparable disease outcomes  
302 (51).

### 303 Model can recapitulate clinical data of varying disease severity across patients

304 In a recent study, patients were stratified by disease outcome and measurements of longitudinal viral load  
305 from their saliva were fit using cubic splines, yielding ribbons of confidence intervals on viral loads for  
306 each category (39). We digitized these ribbons and tested our model predictions against them (figure 4A-  
307 D, grey patches). The study reported data from symptom onset. We therefore added an estimated length  
308 of the prodromal period to the timepoints in order to compare our model predictions. We set this length to  
309 4.8 d from the German transmission chain data (37, 38) (supplementary table S2), which is also consistent  
310 with other reported estimates (33). We estimated the viral load,  $V$ , from our model predictions using the  
311 pseudo-steady state approximation,  $V \approx pI/c$ , where  $p$  is the per capita rate of viral production from  
312 infected cells and  $c$  is the per capita rate of viral clearance. We set  $p$  and  $c$  to values estimated previously  
313 (52) (supplementary text section A).



314

315 **Figure 4: Model recapitulates viral load data from patients with different severities of infection.** (A)  
316 The grey patch, as provided in Silva et al. (39), represents the confidence interval of a cubic spline fitted  
317 to the viral load data from non-hospitalized individuals. Curves depict simulated viral load trajectories in  
318 individuals representative of those in the patch. The scale on the right represents immunopathology. The  
319 immunopathology associated with the simulated trajectories are marked on the scale using arrowheads  
320 having the same colors as the profiles. (B-D) Simulations recapitulating the viral load trajectories from  
321 moderate, severe and deceased patients, respectively. Immunopathology of deceased individuals not  
322 shown were higher than the upper limit of the scale shown here. The blue bar on the scale in (D)  
323 represents the range of immunopathology beyond which fatality is the likely clinical outcome. The  
324 parameters used for each trajectory are in supplementary tables S9-S12. Those associated with the  
325 profiles with dashed lines were used for sensitivity analyses (supplementary figures S9-S12).

---

327 The ribbons of data are not amenable to fitting. We therefore varied parameters associated with the innate  
328 and CD8 T-cell responses in our model to achieve dynamical profiles of viral load resembling the  
329 ribbons. For the purpose of these simulations we ignored both the potential adverse and favorable effects  
330 of antibodies. The ribbon for the non-hospitalized patients was associated with low viral loads (figure  
331 4A). The peak viral load was approximately  $10^6$  copies of viral RNA. This relatively low peak viral load  
332 could be captured by our model when the strength of the innate response was increased, which we  
333 achieved by increasing  $k_5$  and/or  $\epsilon_I$  (supplementary table S9). The duration of the infection was  
334 dependent on the CD8 T-cell response. Strong CD8 T-cell stimulation, achieved with a low value of  $k_p$ ,  
335 led to rapid clearance, whereas weaker stimulation, corresponding to a higher  $k_p$ , allowed the infection to  
336 remain for an extended period. We calculated the immunopathology associated with these simulations and  
337 found it to be low (figure 4A, scale on the right; also see below).

338 The ribbon for patients eliciting moderate symptoms had a relatively higher viral load at the peak,  
339 reaching approximately  $10^8$  copies of viral RNA (figure 4B). Parameters sufficiently close to the  
340 population estimates above allowed us to capture the dynamics for these patients (supplementary table  
341 S10). The associated immunopathology was considerably higher than the non-hospitalized patients. For  
342 severely infected patients, the viral load peak was above  $10^8$ , reaching as high as  $10^{10}$  copies (figure 4C).  
343 We achieved this high peak viral load by lowering the strength of the innate response (decreasing  $k_5$   
344 and/or  $\epsilon_I$ ; see supplementary table S11). The delayed clearance could be recapitulated by lowering CD8  
345 T-cell stimulation (increasing  $k_p$  and/or decreasing  $k_3$ ). The immunopathology was higher than those  
346 calculated to capture the viral load dynamics in moderate patients (compare the scales in figure 4B and  
347 4C). Lastly, for the deceased individuals, the peak viral load was similar to the severe patients. However,  
348 the downward trend in the viral load after the peak seen with the severely infected patients was no longer  
349 apparent (figure 4D). The viral load remained around  $10^8$  RNA copies till day 30 post-exposure. A much  
350 weaker innate response (low  $\epsilon_I$ ) and a weaker CD8 T-cell response (high  $k_p$ ) could generate matching  
351 profiles (supplementary table S12). The immunopathology for the deceased patients was consistently  
352 higher than the severe patients, indicating that there might be an upper limit to the extent of  
353 immunopathological tissue damage that lay somewhere between our estimates for severe and deceased  
354 patients, and crossing which mortality would almost certainly result.

355 Our model thus recapitulated the trends in the viral load seen in patients with different severity of  
356 infection. Furthermore, the model indicated that there should be a narrow range of immunopathology,  
357 which acts as a threshold to determine the fatal outcomes in COVID-19 (figure 4D, scale on the right).



358 To assess whether variations in other model parameters could also achieve the above trends, we  
359 performed a global sensitivity analysis of our parameters using one representative parameter combination  
360 from each disease outcome category as reference (figure 4A-D, dashed curves; supplementary figures S9-  
361 S12; supplementary tables S9-S12). Specifically, we calculated how sensitive our measure of  
362 immunopathology was to the parameters. We found that immunopathology was most sensitive to  $\varepsilon_I$  and  
363  $k_6$  for non-hospitalized and moderately symptomatic patients (supplementary figures S9, S10). For  
364 severely infected and deceased patients,  $I_{max}$ ,  $k_3$  and  $\varepsilon_I$  emerged as the important parameters  
365 (supplementary figures S11, S12). These results reinforce our expectations above. In mild infections, the  
366 innate immune response is strong and any variation in its strength would have the most influence on  
367 disease severity. In more severe infections, the innate and adaptive responses are both involved and the  
368 severity is therefore sensitive to variations in the strengths of both.

369 Model predictions thus successfully recapitulated the heterogeneous outcomes and the associated  
370 dynamical patterns of SARS-CoV-2 infection.

## 371 Discussion

372 The extreme heterogeneity in the outcomes of SARS-CoV-2 infection across infected individuals has  
373 been puzzling. Here, using mathematical modeling and analysis of patient data, we predict that the  
374 heterogeneity arises from the variations in the strength and the timing of the innate and the CD8 T-cell  
375 responses across individuals. When both the innate and the CD8 T-cell arms are strong, asymptomatic or  
376 mild infections result. When the CD8 T-cell arm is strong, clearance of the infection results. If the innate  
377 arm is weak, the peak viral load can be large, resulting in higher immunopathology and moderate  
378 symptoms. When the CD8 T-cell response is strong but delayed, a predator-prey type interaction between  
379 the innate arm and the virus results, causing multiple peaks in viral load. These oscillations end when the  
380 CD8 T-cell response is mounted, and clearance ensues. When the CD8 T-cell response is weak, but the  
381 innate arm is strong, prolonged infection can result before clearance. When both the arms are weak,  
382 severe infection including mortality follows. These predictions offer a conceptual understanding of the  
383 heterogeneous outcomes of SARS-CoV-2 infection. They also offer a synthesis of the numerous  
384 independent and seemingly disconnected clinical observations associated with the outcomes and present a  
385 framework that may help tune interventions.

386 In the last year, several mathematical models of within-host SAR-CoV-2 dynamics have been developed  
387 and have offered valuable insights (53). For instance, they have helped estimate the within-host basic  
388 reproductive ratio (33, 34, 52) and assess the effects of drugs and vaccines (26, 27, 44, 54–57). Attempts  
389 have also been made to capture the role of the immune system in disease progression and outcome (44,  
390 55, 57–61). Available models, however, have either not been shown to fit longitudinal patient data or  
391 have failed to describe the entire range of outcomes realized. To our knowledge, ours is the first study to  
392 describe the outcomes realized comprehensively using a mathematical model that is consistent with  
393 patient data.

394 Our model predictions help better understand known demographic correlates of disease severity and  
395 mortality, such as gender, age and co-morbidities. In all these cases, as our predictions indicate, more  
396 severe infections are associated with weaker CD8 T-cell responses and/or unregulated innate immune  
397 responses. Male patients trigger higher levels of peripheral cytokine expression and elicit weaker CD8 T-  
398 cell responses than female patients (62), resulting in more frequent severity and mortality in males (43).

399 The increased mortality in the elderly is caused by immunosenescence, which is associated with  
400 decreased proliferative capacity of lymphocytes and impaired functionality of innate immune cells (63).  
401 Increased mortality is also associated with co-morbidities, such as type-2 diabetes (64), where  
402 uncontrolled production of proinflammatory cytokines and inappropriate recruitment of lymphocytes is  
403 observed (65).

404 Factors in addition to the above could contribute to variations in the innate and the CD8 T-cell responses  
405 across individuals. For instance, certain mutations, reported in a subset of severe COVID-19 patients, may  
406 preclude a potent interferon response (47). A section of severely infected patients is reported to harbor  
407 neutralizing autoantibodies against interferons (29, 66). Overzealous production of antibodies against  
408 SARS-CoV-2 might inhibit the pathway for interferon-mediated induction of antiviral genes (67).  
409 Further, in vitro studies suggest that different SARS-CoV-2 proteins can inhibit the TBK1-IRF3 pathway  
410 or the JAK/STAT pathway at several signaling nodes, adversely affecting interferon production and/or  
411 signaling (68). Variability in the CD8 T-cell response may come from different precursor populations,  
412 due for instance to prior exposure to circulating human coronaviruses (50). Patients pre-exposed to other  
413 coronaviruses or rhinoviruses harbor populations of effector T-cells that might cross-react with SARS-  
414 CoV-2 antigens and contribute to the early clearance of the infection (50, 69). Population-level variations  
415 in effector cell frequencies (70) and inter-individual heterogeneity in lymphocytic gene expression  
416 patterns (71) may also contribute to the variability in the CD8 T-cell response.

417 CD8 T-cell exhaustion has been proposed as an evolutionary design to prevent mortality due to  
418 immunopathology (30, 72). By preventing extensive tissue damage due to CD8 T-cell killing of infected  
419 cells, exhaustion can avert mortality. The price of reduced CD8 T-cell efficiency is often persistent  
420 infection, as seen with HIV and hepatitis C (30). With severe SARS-CoV-2 infection, although extensive  
421 CD8 T-cell exhaustion is seen, it appears inadequate to prevent mortality; immunopathology caused by  
422 proinflammatory cytokines dominates. Potent activation of the NF- $\kappa$ B pathway by components of the  
423 SARS-CoV-2 virion may trigger the production of detrimental proinflammatory cytokines (73, 74).  
424 Heightened interferon expression in the lung (5, 18, 19, 75, 76) impairs cell proliferation, impeding tissue  
425 repair after proinflammatory cytokine-mediated immunopathology (77). Moreover, interferons may  
426 synergize with proinflammatory cytokines to fuel immunopathology by triggering cell death pathways  
427 (78, 79). (Note that interferons may be subdued in peripheral circulation (80), but that appears to be  
428 uncorrelated with their expression in the respiratory tract in COVID-19 (5).) In contrast,  
429 immunopathology due to CD8 T-cells appears minimal. CD8 T-cells infiltrate the alveolar tissues of  
430 COVID-19 patients (76) and can kill infected cells. At the peak of the infection,  $10^4$ - $10^6$  cells are  
431 estimated to be infected out of the  $10^{11}$  estimated target cells in the respiratory tract (81). Thus, direct  
432 CD8 T-cell killing of infected cells would affect a small fraction of cells in the respiratory tract. This may  
433 also explain why viral persistence has not been observed with SARS-CoV-2 infection: Inducing CD8 T-  
434 cell exhaustion can only minimally affect immunopathology dominated by cytokines. We speculate that  
435 the absence of persistence may be a general feature of those viral infections where immunopathology is  
436 predominantly cytokine-mediated. Indeed, hypercytokinemia has been associated with the fatal outcomes  
437 following influenza A (H5N1) infection (82).

438 A strategy of great interest today for reinvigorating exhausted CD8 T-cells is the use of immune  
439 checkpoint inhibitors (83). The inhibitors are approved for use in certain cancers. Because of their  
440 promise, five clinical trials are underway for testing their efficacy in treating severe COVID-19, of which



441 one (NCT04333914) is on cancer patients, and the remaining (NCT04413838, NCT04343144,  
442 NCT04356508, and NCT04268537) are on non-cancer patients infected by SARS-CoV-2 (84). A major  
443 risk of checkpoint inhibitor therapy is increased immunopathology due to a heightened CD8 T-cell  
444 response. Based on our model predictions and arguments above, we speculate that with COVID-19, the  
445 risk of increased immunopathology from immune checkpoint inhibitor therapy is likely to be minimal,  
446 given the predominance of cytokine-mediated pathology. Indeed, a retrospective analysis of melanoma  
447 patients showed that checkpoint inhibitor therapy did not increase the risk of mortality due to COVID-19  
448 (85). Rather, the beneficial effects of an improved CD8 T-cell response may outweigh any minimal  
449 enhancement in immunopathology.

450 Our model could be applied to understand the implications of other interventions (86) and of emerging  
451 viral mutants (87) on disease outcomes. Given the mechanisms of action of available drugs and drug  
452 candidates (86), their effects on typical individuals in the mild, moderate and severe infection categories  
453 could be predicted using the corresponding nominal parameter estimates we identified for the respective  
454 categories. Several recently identified circulating mutants are known to be more infectious than the  
455 original SARS-CoV-2 strain and to escape immune responses (88). These characteristics could be  
456 incorporated in our model readily by suitably increasing the infectivity and/or decreasing the strength of  
457 the immune response, to predict how emerging strains could alter the overall severity of the infection. We  
458 recognize that to estimate the effects of such variations at the population level, knowledge of how the  
459 parameter values in our model, particularly those defining the innate and CD8 T-cell responses, are  
460 distributed across individuals in a population would be required. With hepatitis C virus infection, for  
461 instance, the distribution of the strength of interferon responsiveness across individuals quantitatively  
462 predicted the fraction of individuals that spontaneously cleared the infection (89, 90) and together with  
463 the distribution of the CD8 T-cell response captured the success of interferon-based and other therapies  
464 (89–91). Such predictions with SARS-CoV-2, once parameter distributions become available, may help  
465 refine clinical and epidemiological projections of healthcare requirements.

466 Our study has limitations. First, we neglected the role that cytokines play in the expansion of CD8 T-cells  
467 (92) because fits of our model incorporating such an effect to the available data were poor (supplementary  
468 text section B). Perhaps, a larger patient cohort may improve the fits and allow incorporating the latter  
469 effect. Second, our model did not incorporate any negative effect of immunopathology on the immune  
470 response; for instance, lymphopenia (15, 93), which is generally thought to be caused by  
471 immunopathology, could compromise the immune response. Third, we employed a simplified model of  
472 CD8 T-cell exhaustion, following earlier studies (30–32), which allows exhaustion to be reversed fully  
473 upon lowering antigen levels. Recent studies have demonstrated that exhaustion is reversible only in a  
474 subset of exhausted cells (83). Notwithstanding, we expect our key inferences on the roles of the innate  
475 and the CD8 T-cell responses in determining the heterogeneous outcomes of SARS-CoV-2 infection to  
476 hold.

477

## 478 **Methods**

479 **Study design.** We constructed a mathematical model of within-host SARS-CoV-2 infection using  
480 ordinary differential equations. Next, we utilized a nonlinear mixed-effects approach to fit the model to an  
481 available clinical dataset and estimated model parameters (supplementary text, section A, B). The model

482 was then utilized for exploring the effects of parameter variations (figure 3), recapitulating the viral load  
483 trajectories in patients stratified by disease severity (figure 4), and for sensitivity analysis (supplementary  
484 figures S9-S12).

485 **Model construction.** The equations of our model are provided in the results section. The other models  
486 which were fit to the data are described in the supplementary text (supplementary text, section B).

487 **Parameter estimation and model selection.** Published data from Wölfel et al.(37) was digitized by a  
488 custom script in the MATLAB (version R2020a) image analysis toolbox ([www.mathworks.com](http://www.mathworks.com)). This  
489 dataset was further used for fitting different models using the stochastic approximation expectation  
490 maximization (SAEM) algorithm available in Monolix 2020R1 ([www.lixoft.com](http://www.lixoft.com)) (supplementary text,  
491 section A). The Akaike information index (AIC) was calculated within the Monolix environment. The  
492 model with the lowest AIC was selected for further mathematical analysis (supplementary text, section  
493 B).

494 **Fixed points and linear stability analysis.** For the steady-state analysis, estimated parameter values  
495 were utilized. MATLAB (version R2020a) was used to estimate the fixed points of the system and to  
496 determine the nature of their stability. Individual fixed points and their corresponding Jacobian matrices  
497 were estimated using the Symbolic Math Toolbox ([www.mathworks.com](http://www.mathworks.com)). Calculation of the eigenvalues  
498 and eigenvectors for individual fixed points yielded the nature of their stability and facilitated  
499 determination of the phase portraits (supplementary text, section D, supplementary figures S6, S7).

500 **Recapitulating patient viral load data stratified by disease severity.** The published data from Silva et  
501 al. (39), was digitized using a custom MATLAB code, using functions from the image analysis toolbox.  
502 The parameters were manually varied and the quality of the fits determined by visual inspection of the  
503 simulation profile and the confidence interval ribbons.

504 **Sensitivity analysis.** We executed variance based global sensitivity analysis (VBGSA) on the models; the  
505 details of the algorithm have been described elsewhere (94). We simultaneously varied the parameters up  
506 to 5% above and below the population parameters in Monte Carlo simulations and calculated total effect  
507 indices for the parameters (supplementary figures S9-S12).

508

## 509 **Acknowledgments**

510 We thank Pranesh Padmanabhan for insightful comments and Rajat Desikan for help with the Monolix  
511 platform. BC is supported by the C. V. Raman postdoctoral fellowship at the Indian Institute of Science.

## 512 **Author contributions:**

513 Conceptualization: BC, HSS, NMD  
514 Methodology: BC, HSS  
515 Investigation: BC, HSS  
516 Visualization: BC, HSS  
517 Supervision: NMD  
518 Writing—original draft: BC, HSS  
519 Writing—review & editing: BC, HSS, NMD  
520

521  
522 **Competing interests:** None.

523  
524 **Data and materials availability:** All data used in the study are provided in the main text and  
525 supplementary material. Codes are available upon request.

526  
527 **References**

- 528 1. A. Gupta, *et al.*, Extrapulmonary manifestations of COVID-19. *Nat. Med.* **26**, 1017–1032 (2020).
- 529 2. W. Guan, *et al.*, Clinical characteristics of Coronavirus disease 2019 in China. *N. Engl. J. Med.*  
530 **382**, 1708–1720 (2020).
- 531 3. Z. Wu, J. M. McGoogan, Characteristics of and important lessons from the Coronavirus disease  
532 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center  
533 for disease control and prevention. *J. Am. Med. Assoc.* **323**, 1239–1242 (2020).
- 534 4. P. Brodin, Immune determinants of COVID-19 disease presentation and severity. *Nat. Med.* **27**,  
535 28–33 (2021).
- 536 5. B. Sposito, *et al.*, Severity of SARS-CoV-2 infection as a function of the interferon landscape  
537 across the respiratory tract of COVID-19 patients. *bioRxiv*, 2021.03.30.437173 (2021).
- 538 6. J. L. Schultze, A. C. Aschenbrenner, COVID-19 and the human innate immune system. *Cell* **184**,  
539 1671–1692 (2021).
- 540 7. A. Sette, S. Crotty, Adaptive immunity to SARS-CoV-2 and COVID-19. *Cell* **184**, 861–880  
541 (2021).
- 542 8. M. S. Graham, *et al.*, Changes in symptomatology, reinfection, and transmissibility associated  
543 with the SARS-CoV-2 variant B.1.1.7: an ecological study. *Lancet Public Heal.* **6**, e335–e345  
544 (2021).
- 545 9. D. Mercatelli, F. M. Giorgi, Geographic and Genomic Distribution of SARS-CoV-2 Mutations.  
546 *Front. Microbiol.* **11**, 1800 (2020).
- 547 10. A. Park, A. Iwasaki, Type I and Type III Interferons – induction, signaling, evasion, and  
548 application to combat COVID-19. *Cell Host Microbe* **27**, 870–878 (2020).
- 549 11. P. Padmanabhan, U. Garaigorta, N. M. Dixit, Emergent properties of the interferon-signalling  
550 network may underlie the success of hepatitis C treatment. *Nat. Commun.* **5**, 1–9 (2014).
- 551 12. A. T. Tan, *et al.*, Early induction of functional SARS-CoV-2-specific T cells associates with rapid  
552 viral clearance and mild disease in COVID-19 patients. *Cell Rep.* **34**, 108728 (2021).
- 553 13. M. Liao, *et al.*, Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19.  
554 *Nat. Med.* **26**, 842–844 (2020).
- 555 14. J. Y. Zhang, *et al.*, Single-cell landscape of immunological responses in patients with COVID-19.  
556 *Nat. Immunol.* **21**, 1107–1118 (2020).
- 557 15. B. Diao, *et al.*, Reduction and functional exhaustion of T cells in patients with Coronavirus disease  
558 2019 (COVID-19). *Front. Immunol.* **11**, 827 (2020).

- 559 16. A. Bonifacius, *et al.*, COVID-19 immune signatures reveal stable antiviral T cell function despite  
560 declining humoral responses. *Immunity* **54**, 340-354.e6 (2021).
- 561 17. M. Zheng, *et al.*, Functional exhaustion of antiviral lymphocytes in COVID-19 patients. *Cell. Mol.*  
562 *Immunol.* **17**, 533–535 (2020).
- 563 18. A. Broggi, *et al.*, Type III interferons disrupt the lung epithelial barrier upon viral recognition.  
564 *Science (80-. )*. **369**, 706–712 (2020).
- 565 19. A. R. Daamen, *et al.*, Comprehensive transcriptomic analysis of COVID-19 blood, lung, and  
566 airway. *Sci. Rep.* **11**, 1–19 (2021).
- 567 20. D. A. Dorward, *et al.*, Tissue-specific immunopathology in fatal COVID-19. *Am. J. Respir. Crit.*  
568 *Care Med.* **203**, 192–201 (2021).
- 569 21. S. A. Lowery, A. Sariol, S. Perlman, Innate immune and inflammatory responses to SARS-CoV-2:  
570 Implications for COVID-19. *Cell Host Microbe* (2021)  
571 <https://doi.org/10.1016/j.chom.2021.05.004>.
- 572 22. J. Yang, *et al.*, Characteristics of T-cell responses in COVID-19 patients with prolonged  
573 SARS-CoV-2 positivity – a cohort study. *Clin. Transl. Immunol.* **10**, e1259 (2021).
- 574 23. J. Sun, *et al.*, Prolonged persistence of SARS-CoV-2 RNA in body fluids. *Emerg. Infect. Dis.* **26**,  
575 1834–1838 (2020).
- 576 24. N. Li, X. Wang, T. Lv, Prolonged SARS-CoV-2 RNA shedding: Not a rare phenomenon. *J. Med.*  
577 *Viol.* **92**, 2286–2287 (2020).
- 578 25. Q. X. Long, *et al.*, Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nat. Med.* **26**,  
579 845–848 (2020).
- 580 26. D. S. Khoury, *et al.*, Neutralizing antibody levels are highly predictive of immune protection from  
581 symptomatic SARS-CoV-2 infection. *Nat. Med.*, 1–7 (2021).
- 582 27. P. Padmanabhan, R. Desikan, N. M. Dixit, Modelling the population-level protection conferred by  
583 COVID-19 vaccination 1 2. *medRxiv*, 2021.03.16.21253742 (2021).
- 584 28. C. Lucas, *et al.*, Delayed production of neutralizing antibodies correlates with fatal COVID-19.  
585 *Nat. Med.*, 1–9 (2021).
- 586 29. E. Y. Wang, *et al.*, Diverse Functional Autoantibodies in Patients with COVID-19. *Nature*, 1–9  
587 (2021).
- 588 30. S. Baral, R. Antia, N. M. Dixit, A dynamical motif comprising the interactions between antigens  
589 and CD8 T cells may underlie the outcomes of viral infections. *Proc. Natl. Acad. Sci. U. S. A.* **116**,  
590 17393–17398 (2019).
- 591 31. S. M. Kahan, E. J. Wherry, A. J. Zajac, T cell exhaustion during persistent viral infections.  
592 *Virology* **479–480**, 180–193 (2015).
- 593 32. J. M. Conway, A. S. Perelson, Post-treatment control of HIV infection. *Proc. Natl. Acad. Sci. U. S.*  
594 *A.* **112**, 5467–5472 (2015).
- 595 33. N. Néant, *et al.*, Modeling SARS-CoV-2 viral kinetics and association with mortality in

- 596 hospitalized patients from the French COVID cohort. *Proc. Natl. Acad. Sci. U. S. A.* **118** (2021).
- 597 34. K. S. Kim, *et al.*, A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV,  
598 and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2.  
599 *PLoS Biol.* **19**, e3001128 (2021).
- 600 35. S. A. Lauer, *et al.*, The incubation period of coronavirus disease 2019 (CoVID-19) from publicly  
601 reported confirmed cases: Estimation and application. *Ann. Intern. Med.* **172**, 577–582 (2020).
- 602 36. N. Le Bert, *et al.*, Highly functional virus-specific cellular immune response in asymptomatic  
603 SARS-CoV-2 infection. *J. Exp. Med.* **218** (2021).
- 604 37. R. Wölfel, *et al.*, Virological assessment of hospitalized patients with COVID-2019. *Nature* **581**,  
605 465–469 (2020).
- 606 38. M. M. Böhmer, *et al.*, Investigation of a COVID-19 outbreak in Germany resulting from a single  
607 travel-associated primary case: a case series. *Lancet Infect. Dis.* **20**, 920–928 (2020).
- 608 39. J. Silva, *et al.*, Saliva viral load is a dynamic unifying correlate of COVID-19 severity and  
609 mortality. *medRxiv Prepr. Serv. Heal. Sci.* (2021) <https://doi.org/10.1101/2021.01.04.21249236>  
610 (April 5, 2021).
- 611 40. A. Mohammadi, E. Esmailzadeh, Y. Li, R. J. Bosch, J. Z. Li, SARS-CoV-2 detection in different  
612 respiratory sites: A systematic review and meta-analysis. *EBioMedicine* **59** (2020).
- 613 41. M. Lavielle, F. Mentré, Estimation of population pharmacokinetic parameters of saquinavir in  
614 HIV patients with the MONOLIX software. *J. Pharmacokinet. Pharmacodyn.* **34**, 229–249 (2007).
- 615 42. J. E. Pearson, P. Krapivsky, A. S. Perelson, Stochastic theory of early viral infection: Continuous  
616 versus burst production of virions. *PLoS Comput. Biol.* **7**, 1001058 (2011).
- 617 43. C. J. E. Metcalf, B. T. Grenfell, A. L. Graham, Disentangling the dynamical underpinnings of  
618 differences in SARS-CoV-2 pathology using within-host ecological models. *PLoS Pathog.* **16**,  
619 e1009105 (2020).
- 620 44. R. Ke, C. Zitzmann, R. M. Ribeiro, A. S. Perelson, Kinetics of SARS-CoV-2 infection in the  
621 human upper and lower respiratory tracts and their relationship with infectiousness. *medRxiv*,  
622 2020.09.25.20201772 (2020).
- 623 45. C. Lucas, *et al.*, Longitudinal analyses reveal immunological misfiring in severe COVID-19.  
624 *Nature* **584**, 463–469 (2020).
- 625 46. Y. Peng, *et al.*, Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in  
626 UK convalescent individuals following COVID-19. *Nat. Immunol.* **21**, 1336–1345 (2020).
- 627 47. Q. Zhang, *et al.*, Inborn errors of type I IFN immunity in patients with life-threatening COVID-19.  
628 *Science (80-. ).* **370** (2020).
- 629 48. A. G. Laing, *et al.*, A dynamic COVID-19 immune signature includes associations with poor  
630 prognosis. *Nat. Med.* **26**, 1623–1635 (2020).
- 631 49. J. Fajnzylber, *et al.*, SARS-CoV-2 viral load is associated with increased disease severity and  
632 mortality. *Nat. Commun.* **11**, 1–9 (2020).



- 633 50. K. E. Lineburg, *et al.*, CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid  
634 epitope cross-react with selective seasonal coronaviruses. *Immunity* **54**, 1055-1065.e5 (2021).
- 635 51. A. Chandrashekar, *et al.*, SARS-CoV-2 infection protects against rechallenge in rhesus macaques.  
636 *Science* (80-. ). **369**, 812–817 (2020).
- 637 52. S. Wang, *et al.*, Modeling the viral dynamics of SARS-CoV-2 infection. *Math. Biosci.* **328**,  
638 108438 (2020).
- 639 53. A. S. Perelson, R. Ke, Mechanistic Modeling of SARS-CoV-2 and Other Infectious Diseases and  
640 the Effects of Therapeutics. *Clin. Pharmacol. Ther.* **109**, 829–840 (2021).
- 641 54. A. Gonçalves, *et al.*, Timing of Antiviral Treatment Initiation is Critical to Reduce SARS-CoV-2  
642 Viral Load. *CPT Pharmacometrics Syst. Pharmacol.* **9**, 509–514 (2020).
- 643 55. A. Goyal, E. F. Cardozo-Ojeda, J. T. Schiffer, Potency and timing of antiviral therapy as  
644 determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response. *Sci.*  
645 *Adv.* **6**, eabc7112 (2020).
- 646 56. P. Padmanabhan, R. Desikan, N. M. Dixit, Targeting TMPRSS2 and Cathepsin B/L together may  
647 be synergistic against SARSCoV- 2 infection. *PLoS Comput. Biol.* **16**, e1008461 (2020).
- 648 57. C. Voutouri, *et al.*, In silico dynamics of COVID-19 phenotypes for optimizing clinical  
649 management. *Res. Sq.* (2020) <https://doi.org/10.21203/rs.3.rs-71086/v1> (April 17, 2021).
- 650 58. E. A. Hernandez-Vargas, J. X. Velasco-Hernandez, In-host Mathematical Modelling of COVID-  
651 19 in Humans. *Annu. Rev. Control* **50**, 448–456 (2020).
- 652 59. S. Sahoo, S. Jhunjhunwala, M. K. Jolly, The good, the bad and the ugly: a mathematical model  
653 investigates the differing outcomes among CoVID-19 patients. *J. Indian Inst. Sci.* **100**, 673–681  
654 (2020).
- 655 60. N. T. Fadai, *et al.*, Infection, inflammation and intervention: Mechanistic modelling of epithelial  
656 cells in COVID-19. *J. R. Soc. Interface* **18** (2021).
- 657 61. A. Bouchnita, A. Tokarev, V. Volpert, A multiscale model suggests that a moderately weak  
658 inhibition of SARS-COV-2 replication by type I IFN could accelerate the clearance of the virus.  
659 *bioRxiv*, 2021.01.25.427896 (2021).
- 660 62. T. Takahashi, *et al.*, Sex differences in immune responses that underlie COVID-19 disease  
661 outcomes. *Nature* **588**, 315–320 (2020).
- 662 63. S. J. Kang, S. I. Jung, Age-related morbidity and mortality among patients with COVID-19. *Infect.*  
663 *Chemother.* **52**, 154–164 (2020).
- 664 64. N. Holman, *et al.*, Risk factors for COVID-19-related mortality in people with type 1 and type 2  
665 diabetes in England: a population-based cohort study. *Lancet Diabetes Endocrinol.* **8**, 823–833  
666 (2020).
- 667 65. A. Berbudi, N. Rahmadika, A. I. Tjahjadi, R. Ruslami, Type 2 Diabetes and its Impact on the  
668 Immune System. *Curr. Diabetes Rev.* **16**, 442–449 (2019).
- 669 66. P. Bastard, *et al.*, Autoantibodies against type I IFNs in patients with life-threatening COVID-19.  
670 *Science* (80-. ). **370** (2020).

- 671 67. A. J. Combes, *et al.*, Global absence and targeting of protective immune states in severe COVID-  
672 19. *Nature* **591**, 124–130 (2021).
- 673 68. H. Xia, *et al.*, Evasion of Type I Interferon by SARS-CoV-2. *Cell Rep.* **33**, 108234 (2020).
- 674 69. J. Mateus, *et al.*, Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans.  
675 *Science (80-. )*. **370**, 89–94 (2020).
- 676 70. P. Brodin, M. M. Davis, Human immune system variation. *Nat. Rev. Immunol.* **17**, 21–29 (2017).
- 677 71. C. J. Ye, *et al.*, Intersection of population variation and autoimmunity genetics in human T cell  
678 activation. *Science (80-. )*. **345** (2014).
- 679 72. D. E. Speiser, *et al.*, T cell differentiation in chronic infection and cancer: Functional adaptation or  
680 exhaustion? *Nat. Rev. Immunol.* **14**, 768–774 (2014).
- 681 73. Y. Wu, *et al.*, RNA-induced liquid phase separation of SARS-CoV-2 nucleocapsid protein  
682 facilitates NF- $\kappa$ B hyper-activation and inflammation. *Signal Transduct. Target. Ther.* **6**, 167  
683 (2021).
- 684 74. C. Neufeldt, *et al.*, SARS-CoV-2 infection induces a pro-inflammatory cytokine response through  
685 cGAS-STING and NF- $\kappa$ B. *bioRxiv*, 2020.07.21.212639 (2020).
- 686 75. Z. Zhou, *et al.*, Heightened innate immune responses in the respiratory tract of COVID-19  
687 patients. *Cell Host Microbe* **27**, 883-890.e2 (2020).
- 688 76. R. Nienhold, *et al.*, Two distinct immunopathological profiles in autopsy lungs of COVID-19. *Nat.*  
689 *Commun.* **11**, 1–13 (2020).
- 690 77. J. Major, *et al.*, Type I and III interferons disrupt lung epithelial repair during recovery from viral  
691 infection. *Science (80-. )*. **369**, 712–717 (2020).
- 692 78. B. Israelow, *et al.*, Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon  
693 signaling. *J. Exp. Med.* **217** (2020).
- 694 79. R. Karki, *et al.*, Synergism of TNF- $\alpha$  and IFN- $\gamma$  triggers inflammatory cell death, tissue damage,  
695 and mortality in SARS-CoV-2 infection and cytokine shock syndromes. *Cell* **184**, 149-168.e17  
696 (2021).
- 697 80. J. Hadjadj, *et al.*, Impaired type I interferon activity and inflammatory responses in severe  
698 COVID-19 patients. *Science (80-. )*. **369**, 718–724 (2020).
- 699 81. R. Sender, *et al.*, The total number and mass of SARS-CoV-2 virions. *Proc. Natl. Acad. Sci.* **118**,  
700 e2024815118 (2021).
- 701 82. M. D. De Jong, *et al.*, Fatal outcome of human influenza A (H5N1) is associated with high viral  
702 load and hypercytokinemia. *Nat. Med.* **12**, 1203–1207 (2006).
- 703 83. M. Hashimoto, *et al.*, CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for  
704 Interventions. *Annu. Rev. Med.* **69**, 301–318 (2018).
- 705 84. S. Vivarelli, *et al.*, Immune-checkpoint inhibitors from cancer to COVID-19: A promising avenue  
706 for the treatment of patients with COVID-19 (Review). *Int. J. Oncol.* **58**, 145–157 (2021).



- 707 85. M. Gonzalez-Cao, *et al.*, Cancer immunotherapy does not increase the risk of death by COVID-19  
708 in melanoma patients. *medRxiv*, 2020.05.19.20106971 (2020).
- 709 86. L. Riva, *et al.*, Discovery of SARS-CoV-2 antiviral drugs through large-scale compound  
710 repurposing. *Nature* **586**, 113–119 (2020).
- 711 87. N. G. Davies, *et al.*, Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in  
712 England. *Science* (80-. ). **372**, eabg3055 (2021).
- 713 88. W. F. Garcia-Beltran, *et al.*, Multiple SARS-CoV-2 variants escape neutralization by vaccine-  
714 induced humoral immunity. *Cell* **184**, 2372-2383.e9 (2021).
- 715 89. V. Venugopal, P. Padmanabhan, R. Raja, N. M. Dixit, Modelling how responsiveness to interferon  
716 improves interferon-free treatment of hepatitis C virus infection. *PLoS Comput. Biol.* **14**,  
717 e1006335 (2018).
- 718 90. R. Raja, S. Baral, N. M. Dixit, Interferon at the cellular, individual, and population level in  
719 hepatitis C virus infection: Its role in the interferon-free treatment era. *Immunol. Rev.* **285**, 55–71  
720 (2018).
- 721 91. N. M. Dixit, J. E. Layden-Almer, T. J. Layden, A. S. Perelson, Modelling how ribavirin improves  
722 interferon response rates in hepatitis C virus infection. *Nature* **432**, 922–924 (2004).
- 723 92. A. Iwasaki, R. Medzhitov, Control of adaptive immunity by the innate immune system. *Nat.*  
724 *Immunol.* **16** (2015).
- 725 93. Z. Chen, E. John Wherry, T cell responses in patients with COVID-19. *Nat. Rev. Immunol.* **20**,  
726 529–536 (2020).
- 727 94. B. Chatterjee, *et al.*, Late-phase synthesis of I $\kappa$ B $\alpha$  insulates the TLR4-activated canonical NF- $\kappa$ B  
728 pathway from noncanonical NF- $\kappa$ B signaling in macrophages. *Sci. Signal.* **9** (2016).
- 729